A distinctive ovarian cancer molecular subgroup characterized by poor prognosis and somatic focal copy number amplifications at chromosome 19

Gynecologic Oncology

Volumn 132, Issue 2, 2014, Pages 343-350

  Sung, Chang Ohk ^a   Song, In Hye ^a   Sohn, Insuk ^b  

^a University of Ulsan College of Medicine   (South Korea)

^b Samsung Advanced Institute of Technology (SAIT)   (South Korea)

Author keywords

Carcinoma; Clustering; Copy number; Ovary; Prognosis; Serous

Indexed keywords

CARCINOMA; CLUSTERING; COPY NUMBER; OVARY; PROGNOSIS; SEROUS;

CHROMOSOMES, HUMAN, PAIR 19; CLUSTER ANALYSIS; CYSTADENOCARCINOMA, SEROUS; DISEASE-FREE SURVIVAL; FEMALE; GENE AMPLIFICATION; GENE DOSAGE; GENE EXPRESSION PROFILING; HUMANS; MIDDLE AGED; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84894041222     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2013.11.036     Document Type: Article

References (39)

1. P.P. Koonings, K. Campbell, D.R. Mishell Jr., and D.A. Grimes Relative frequency of primary ovarian neoplasms: a 10-year review Obstet Gynecol 74 1989 921 926
2. M.A. Bookman Developmental chemotherapy and management of recurrent ovarian cancer J Clin Oncol 21 2003 149s 167s
3. D.S. Miller, J.A. Blessing, C.N. Krasner, R.S. Mannel, P. Hanjani, and M.L. Pearl et al. Phase II evaluation of pemetrexed in the treatment of recurrent or persistent platinum-resistant ovarian or primary peritoneal carcinoma: a study of the Gynecologic Oncology Group J Clin Oncol 27 2009 2686 2691
4. D.J. Gallagher, J.A. Konner, K.M. Bell-McGuinn, J. Bhatia, P. Sabbatini, and C.A. Aghajanian et al. Survival in epithelial ovarian cancer: a multivariate analysis incorporating BRCA mutation status and platinum sensitivity Ann Oncol 22 2011 1127 1132
5. R.A. Lacour, S.N. Westin, L.A. Meyer, S.N. Wingo, J.O. Schorge, and R. Brooks et al. Improved survival in non-Ashkenazi Jewish ovarian cancer patients with BRCA1 and BRCA2 gene mutations Gynecol Oncol 121 2011 358 363
6. D. Yang, S. Khan, Y. Sun, K. Hess, I. Shmulevich, and A.K. Sood et al. Association of BRCA1 and BRCA2 mutations with survival, chemotherapy sensitivity, and gene mutator phenotype in patients with ovarian cancer JAMA 306 2011 1557 1565
7. The Cancer Genome Atlas Integrated genomic analyses of ovarian carcinoma Nature 474 2011 609 615
8. D.D. Bowtell The genesis and evolution of high-grade serous ovarian cancer Nat Rev Cancer 10 2010 803 808
9. V. Brower Ovarian cancer genome sequencing unveils findings J Natl Cancer Inst 103 2011 1288 1290
10. T. Santarius, J. Shipley, D. Brewer, M.R. Stratton, and C.S. Cooper A census of amplified and overexpressed human cancer genes Nat Rev Cancer 10 2010 59 64
11. C.H. Mermel, S.E. Schumacher, B. Hill, M.L. Meyerson, R. Beroukhim, and G. Getz GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers Genome Biol 12 2011 R41
12. I. Sohn, W.Y. Jung, and C.O. Sung Somatic hypermutation and outcomes of platinum based chemotherapy in patients with high grade serous ovarian cancer Gynecol Oncol 126 2012 103 108
13. I. Sohn, and C.O. Sung Predictive modeling using a somatic mutational profile in ovarian high grade serous carcinoma PLoS One 8 2013 e54089
14. R. Beroukhim, G. Getz, L. Nghiemphu, J. Barretina, T. Hsueh, and D. Linhart et al. Assessing the significance of chromosomal aberrations in cancer: methodology and application to glioma Proc Natl Acad Sci U S A 104 2007 20007 20012
15. R. Simon, A. Lam, M.C. Li, M. Ngan, S. Menenzes, and Y. Zhao Analysis of gene expression data using BRB-ArrayTools Cancer Inf 3 2007 11 17
16. G. Dennis Jr., B.T. Sherman, D.A. Hosack, J. Yang, W. Gao, and H.C. Lane et al. DAVID: Database for Annotation, Visualization, and Integrated Discovery Genome Biol 4 2003 P3
17. W. Huang da, B.T. Sherman, and R.A. Lempicki Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources Nat Protoc 4 2009 44 57
18. Z. Lei, I.B. Tan, K. Das, N. Deng, H. Zouridis, and S. Pattison et al. Identification of molecular subtypes of gastric cancer with different responses to PI3-kinase inhibitors and 5-fluorouracil Gastroenterology 145 2013 554 565
19. S. Monti, P. Tamayo, J. Mesirov, and T. Golub Consensus clustering: a resampling-based method for class discovery and visualization of gene expression microarray data Mach Learn 52 2003 91 118
20. J.P. Brunet, P. Tamayo, T.R. Golub, and J.P. Mesirov Metagenes and molecular pattern discovery using matrix factorization Proc Natl Acad Sci U S A 101 2004 4164 4169
21. M. Reich, T. Liefeld, J. Gould, J. Lerner, P. Tamayo, and J.P. Mesirov GenePattern 2.0 Nat Genet 38 2006 500 501
22. J. Gao, B.A. Aksoy, U. Dogrusoz, G. Dresdner, B. Gross, and S.O. Sumer et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal Sci Signal 6 2013 pl1
23. H.K. Dressman, A. Berchuck, G. Chan, J. Zhai, A. Bild, and R. Sayer et al. An integrated genomic-based approach to individualized treatment of patients with advanced-stage ovarian cancer J Clin Oncol 25 2007 517 525
24. R.W. Tothill, A.V. Tinker, J. George, R. Brown, S.B. Fox, and S. Lade et al. Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome Clin Cancer Res 14 2008 5198 5208
25. K. Kawamura, H. Izumi, Z. Ma, R. Ikeda, M. Moriyama, and T. Tanaka et al. Induction of centrosome amplification and chromosome instability in human bladder cancer cells by p53 mutation and cyclin E overexpression Cancer Res 64 2004 4800 4809
26. M.F. Buckley, K.J. Sweeney, J.A. Hamilton, R.L. Sini, D.L. Manning, and R.I. Nicholson et al. Expression and amplification of cyclin genes in human breast cancer Oncogene 8 1993 2127 2133
27. C. Geisen, and T. Moroy The oncogenic activity of cyclin E is not confined to Cdk2 activation alone but relies on several other, distinct functions of the protein J Biol Chem 277 2002 39909 39918
28. M. Stamatakos, V. Palla, I. Karaiskos, K. Xiromeritis, I. Alexiou, and I. Pateras et al. Cell cyclins: triggering elements of cancer or not? World J Surg Oncol 8 2010 111
29. F. Micci, R.I. Skotheim, L. Haugom, J. Weimer, A.M. Eibak, and V.M. Abeler et al. Array-CGH analysis of microdissected chromosome 19 markers in ovarian carcinoma identifies candidate target genes Genes Chromosomes Cancer 49 2010 1046 1053
30. D. Etemadmoghadam, A. deFazio, R. Beroukhim, C. Mermel, J. George, and G. Getz et al. Integrated genome-wide DNA copy number and expression analysis identifies distinct mechanisms of primary chemoresistance in ovarian carcinomas Clin Cancer Res 15 2009 1417 1427
31. N. Nakayama, K. Nakayama, Y. Shamima, M. Ishikawa, A. Katagiri, and K. Iida et al. Gene amplification CCNE1 is related to poor survival and potential therapeutic target in ovarian cancer Cancer 116 2010 2621 2634
32. M. Shih Ie, K. Nakayama, G. Wu, N. Nakayama, J. Zhang, and T.L. Wang Amplification of the ch19p13.2 NACC1 locus in ovarian high-grade serous carcinoma Mod Pathol 24 2011 638 645
33. R. Kuuselo, R. Simon, R. Karhu, P. Tennstedt, A.H. Marx, and J.R. Izbicki et al. 19q13 amplification is associated with high grade and stage in pancreatic cancer Genes Chromosomes Cancer 49 2010 569 575
34. W. Onkes, R. Fredrik, F. Micci, B.J. Schonbeck, J.I. Martin-Subero, and R. Ullmann et al. Breakpoint characterization of the der(19)t(11;19)(q13;p13) in the ovarian cancer cell line SKOV-3 Genes Chromosomes Cancer 52 2013 512 522
35. P.M. Haverty, L.S. Hon, J.S. Kaminker, J. Chant, and Z. Zhang High-resolution analysis of copy number alterations and associated expression changes in ovarian tumors BMC Med Genomics 2 2009 21
36. L. Osterberg, K. Levan, K. Partheen, K. Helou, and G. Horvath Cytogenetic analysis of carboplatin resistance in early-stage epithelial ovarian carcinoma Cancer Genet Cytogenet 163 2005 144 150
37. A. Staebler, B. Karberg, J. Behm, P. Kuhlmann, U. Neubert, and H. Schmidt et al. Chromosomal losses of regions on 5q and lack of high-level amplifications at 8q24 are associated with favorable prognosis for ovarian serous carcinoma Genes Chromosomes Cancer 45 2006 905 917
38. Z.C. Wang, N.J. Birkbak, A.C. Culhane, R. Drapkin, A. Fatima, and R. Tian et al. Profiles of genomic instability in high-grade serous ovarian cancer predict treatment outcome Clin Cancer Res 18 2012 5806 5815
39. D.A. Engler, S. Gupta, W.B. Growdon, R.I. Drapkin, M. Nitta, and P.A. Sergent et al. Genome wide DNA copy number analysis of serous type ovarian carcinomas identifies genetic markers predictive of clinical outcome PLoS One 7 2012 e30996